Yipinhong Pharmaceutical Co Ltd
SZSE:300723
Intrinsic Value
ApicHope Pharmaceutical Co., Ltd. engages in the research and development, production and sale of chemical medicine and traditional Chinese medicine products. [ Read More ]
The intrinsic value of one
Yipinhong Pharmaceutical Co Ltd
stock under the Base Case scenario is
23.26
CNY.
Compared to the current market price of 21.01 CNY,
Yipinhong Pharmaceutical Co Ltd
is
Undervalued by 10%.
Yipinhong Pharmaceutical Co Ltd's market capitalization is 9B CNY.
Yipinhong Pharmaceutical Co Ltd stock price is 21.01 CNY.
Yipinhong Pharmaceutical Co Ltd stock price (21.01 CNY) is 10% less than its Intrinsic Value (23.26 CNY).
Yipinhong Pharmaceutical Co Ltd stock (16.84 CNY) is 20% less than its price (21.01 CNY). Open DCF Valuation
Yipinhong Pharmaceutical Co Ltd stock price (21.01 CNY) is 29% less than its Relative Value (29.67 CNY). Open Relative Valuation
Yipinhong Pharmaceutical Co Ltd has upside potential of 70% compared to the average analyst price target.
Open Wall St Estimates
Yipinhong Pharmaceutical Co Ltd has positive three-year average ROIC (Return on Invested Capital): 10%. The company is efficient at using invested capital to generate operating income.
Yipinhong Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) for the past 12 months is positive and is equal to 8%.
Yipinhong Pharmaceutical Co Ltd's ROE (Return on Equity) has decreased in the last 3 years from 17% to 14%.
Yipinhong Pharmaceutical Co Ltd's ROE (Return on Equity) for the past 12 months is positive and is equal to 14%.
Yipinhong Pharmaceutical Co Ltd has positive Operating Income for the last twelve months.
Yipinhong Pharmaceutical Co Ltd has positive Net Income for the last twelve months.
Yipinhong Pharmaceutical Co Ltd's ROIC (Return on Invested Capital) has decreased in the last 3 years from 12% to 8%.
Yipinhong Pharmaceutical Co Ltd's Revenue has grown by 16% over the past 12 months.
Yipinhong Pharmaceutical Co Ltd's short-term assets (1B CNY) exceed its short-term liabilties (1B CNY).
Yipinhong Pharmaceutical Co Ltd has positive three-year average ROE (Return on Equity): 16%. The company is efficient at transforming stockholders' equity into net income.
Yipinhong Pharmaceutical Co Ltd's Revenue has been growing by 15% per year for the last 3 years.
Yipinhong Pharmaceutical Co Ltd's Revenue is forecast to grow at a rate of 25% per year over the next 3 years.
Yipinhong Pharmaceutical Co Ltd has positive Net Debt. This means that the company has more debt (1B CNY) than cash and short-term investments (488m CNY).
Yipinhong Pharmaceutical Co Ltd has positive Free Cash Flow for the last twelve months.
Yipinhong Pharmaceutical Co Ltd's long-term assets (4B CNY) exceed its long-term liabilties (2B CNY).
Yipinhong Pharmaceutical Co Ltd's D/E (Debt to Equity) is very low and is equal to 0.56.
Yipinhong Pharmaceutical Co Ltd has positive Gross Profit for the last twelve months.
Yipinhong Pharmaceutical Co Ltd's Altman Z-Score is very high and is equal to 5.05.
Valuation Backtest
Yipinhong Pharmaceutical Co Ltd
Run backtest to discover the historical profit from buying and selling
Yipinhong Pharmaceutical Co Ltd
stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Yipinhong Pharmaceutical Co Ltd
Balance Sheet Decomposition
Yipinhong Pharmaceutical Co Ltd
| Current Assets | 1.5B |
| Cash & Short-Term Investments | 488.2m |
| Receivables | 297.7m |
| Other Current Assets | 712.3m |
| Non-Current Assets | 2.7B |
| Long-Term Investments | 541.2m |
| PP&E | 1.6B |
| Intangibles | 453m |
| Other Non-Current Assets | 97.3m |
| Current Liabilities | 1.2B |
| Accounts Payable | 57.9m |
| Accrued Liabilities | 46m |
| Short-Term Debt | 851.1m |
| Other Current Liabilities | 246.9m |
| Non-Current Liabilities | 679.3m |
| Long-Term Debt | 453.7m |
| Other Non-Current Liabilities | 225.5m |
Earnings Waterfall
Yipinhong Pharmaceutical Co Ltd
|
Revenue
|
2.5B
CNY
|
|
Cost of Revenue
|
-468m
CNY
|
|
Gross Profit
|
2B
CNY
|
|
Operating Expenses
|
-1.7B
CNY
|
|
Operating Income
|
355.3m
CNY
|
|
Other Expenses
|
-48.7m
CNY
|
|
Net Income
|
306.7m
CNY
|
Free Cash Flow Analysis
Yipinhong Pharmaceutical Co Ltd
What is Free Cash Flow?
Profitability Score
Profitability Due Diligence
Yipinhong Pharmaceutical Co Ltd's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Score
Yipinhong Pharmaceutical Co Ltd's profitability score is 56/100. The higher the profitability score, the more profitable the company is.
Solvency Score
Solvency Due Diligence
Yipinhong Pharmaceutical Co Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Score
Yipinhong Pharmaceutical Co Ltd's solvency score is 64/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
Price Targets Summary
Yipinhong Pharmaceutical Co Ltd
According to Wall Street analysts, the average 1-year price target for
Yipinhong Pharmaceutical Co Ltd
is 35.62 CNY
with a low forecast of 32.18 CNY and a high forecast of 40.95 CNY.
Shareholder Return
Price
Yipinhong Pharmaceutical Co Ltd
| Average Annual Return | 11.97% |
| Standard Deviation of Annual Returns | 35.53% |
| Max Drawdown | -94% |
| Market Capitalization | 9B CNY |
| Shares Outstanding | 454 143 281 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Yipinhong Pharmaceutical Co Ltd
Country
Industry
Market Cap
Dividend Yield
Description
ApicHope Pharmaceutical Co., Ltd. engages in the research and development, production and sale of chemical medicine and traditional Chinese medicine products. The company is headquartered in Guangzhou, Guangdong and currently employs 1,079 full-time employees. The company went IPO on 2017-11-16. The firm has two types of products which are children's drugs and chronic disease drugs. The children's drugs are used for the treatment of colds, digestive anorexia, viral infections, children's eczema and other diseases, including clindamycin palmitate dispersible tablets and clindamycin palmitate granules. The chronic disease drugs include hepatocyte growth-promoting hormone for injection, aceglutamine for injection and adenosine cyclophosphate for injection, which are used for the treatment of severe viral hepatitis and cardiovascular and cerebrovascular diseases. The firm is also engaged in selling drugs for agents.
Contact
IPO
Employees
Officers
The intrinsic value of one
Yipinhong Pharmaceutical Co Ltd
stock under the Base Case scenario is
23.26
CNY.
Compared to the current market price of 21.01 CNY,
Yipinhong Pharmaceutical Co Ltd
is
Undervalued by 10%.
You don't have any saved screeners yet
